3 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow defactinib: new trials by email Literature Review of defactinib trials Research Report on defactinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK VS-6063, Paclitaxel, Carboplatin - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Michael McHale | 8 | 2018-02-06 | 2026-07-31 |
| Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Part A - VS-6063, Part A - Avelumab - Epithelial Ovarian Cancer | Phase 1 | Terminated | Verastem, Inc. | 98 | 2016-10-01 | 2019-04-30 |
| A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma VS-5584 and VS-6063 - Relapsed Malignant Mesothelioma | Phase 1 | Terminated | Verastem, Inc. | 21 | 2015-01-01 | 2017-01-30 |
Carcinoma, Ovarian Epithelial (1) · Mesothelioma, Malignant (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Verastem, Inc. (2) · Michael McHale (1)
United States (3) · United Kingdom (1)
Hagop Youssoufian (1) · Hagop Youssoufian, MD (1) · Michael McHale (1)